Morrisville, United States
IMMORNA, operational under the slogan "Our RNA Encodes Innovation," is a burgeoning player in the biotechnology sector focusing on mRNA-based therapeutics and vaccines.
Founded in 2019, IMMORNA has quickly established a sophisticated platform for mRNA synthesis, purification, and analytical testing. Its unique approach capitalizes on conventional, self-replicating, and circular mRNA technologies, and its innovative delivery vehicles—featuring proprietary ionizable cationic lipids—allow for versatile administration methods, including intramuscular and intravenous routes.
IMMORNA's research & development pipeline addresses critical areas such as cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology. The company has made significant strides, particularly in advancing oncology and infectious disease treatments to clinical stages.
The company's recent financial boost comes from a Grant investment by the Bill & Melinda Gates Foundation on 01 August 2024. Located in the United States, IMMORNA's growth trajectory and strong intellectual property portfolio position it as an attractive investment opportunity in the biotechnology market.
